Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
J Endocrinol Invest. 2024 Jun;47(6):1457-1465. doi: 10.1007/s40618-023-02257-3. Epub 2024 Jan 12.
This study aimed to assess the long-term outcome of patients with acromegaly.
This is a multicenter, retrospective, observational study which extends the mean observation period of a previously reported cohort of Italian patients with acromegaly to 15 years of follow-up.
Only patients from the centers that provided information on the life status of at least 95% of their original cohorts were included. Life status information was collected either from clinical records or from the municipal registry offices. Standardized mortality ratios (SMRs) were computed comparing data with those of the general Italian population.
A total of 811 patients were included. There were 153 deaths, with 90 expected and an SMR of 1.7 (95% CI 1.4-2.0, p < 0.001). Death occurred after a median of 15 (women) or 16 (men) years from the diagnosis, without gender differences. Mortality remained elevated in the patients with control of disease (SMR 1.3, 95% CI 1.1-1.6). In the multivariable analysis, only older age and high IGF1 concentrations at last available follow-up visit were predictors of mortality. The oncological causes of death outweighed the cardiovascular ones, bordering on statistical significance with respect to the general population.
Mortality remains significantly high in patients with acromegaly, irrespectively of disease status, as long as the follow-up is sufficiently long with a low rate of patients lost to follow-up. Therapy strategy including radiotherapy does not have an impact on mortality. Oncological causes of death currently outweigh the cardiovascular causes.
本研究旨在评估肢端肥大症患者的长期预后。
这是一项多中心、回顾性、观察性研究,将意大利肢端肥大症患者队列的先前报告的平均观察期延长至 15 年随访。
仅纳入那些提供了其原始队列中至少 95%患者的生存状态信息的中心的患者。生存状态信息是从临床记录或市政登记处收集的。通过与意大利普通人群的数据进行比较来计算标准化死亡率比(SMR)。
共纳入 811 例患者。共发生 153 例死亡,其中 90 例为预期死亡,SMR 为 1.7(95%CI 1.4-2.0,p<0.001)。从诊断后中位数 15 年(女性)或 16 年(男性)死亡,无性别差异。疾病控制的患者死亡率仍然升高(SMR 1.3,95%CI 1.1-1.6)。在多变量分析中,只有年龄较大和最后一次随访时 IGF1 浓度较高是死亡的预测因素。肿瘤死亡原因超过心血管死亡原因,与普通人群相比接近统计学意义。
只要随访时间足够长且失访率低,肢端肥大症患者的死亡率仍然显著升高,无论疾病状况如何。包括放疗在内的治疗策略对死亡率没有影响。目前肿瘤死亡原因超过心血管死亡原因。